Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 17/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29453067 | 0.79 | IDO1 (0.65) | IDO1CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL13517203 | 0.79 | IDO1 (0.66) | IDO1CYP3A4ADRA2AADRA2BHPGDS | |
| SCHEMBL1950648 | 0.79 | IDO1 (1.00) | IDO1CYP3A4ADRA2AADRA2B | |
| SCHEMBL26259992 | 0.78 | ADRA2A (0.66) | IDO1CYP3A4ADRA2AADRA2B | |
| SCHEMBL26259980 | 0.78 | IDO1 (0.64) | IDO1CYP3A4ADRA2AADRA2BHPGDS | |
| SCHEMBL1902603 | 0.78 | IDO1 (1.00) | IDO1CYP3A4ADRA2AADRA2BHPGDS | |
| SCHEMBL7503338 | 0.78 | IDO1 (0.63) | IDO1CYP3A4ADRA2AADRA2BHPGDS | |
| SCHEMBL871312 | 0.78 | IDO1 (0.63) | IDO1CYP3A4ADRA2AADRA2BHPGDS | |
| SCHEMBL1951228 | 0.78 | IDO1 (1.00) | IDO1CYP3A4ADRA2AADRA2BHPGDS | |
| SCHEMBL30538054 | 0.78 | IDO1 (0.63) | IDO1CYP3A4ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174942-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2015-11-03 | — | — | US | claimed |
| US-20140323740-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-10-30 | — | — | US | claimed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | claimed |
| US-9174942-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174942-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-8900722-B2 | OLED device employing alkali metal cluster compounds | GLOBAL OLED TECHNOLOGY LLC (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140323740-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-10-30 | — | — | US | disclosed |
| US-8748469-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748469-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2009132238-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090142618-A1 | OLED DEVICE EMPLOYING ALKALI METAL CLUSTER COMPOUNDS | GLOBAL OLED TECHNOLOGY LLC | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090142618-A1 | OLED DEVICE EMPLOYING ALKALI METAL CLUSTER COMPOUNDS | OCIAD2, OCIAD1, OSTC | IDO1 1164/4885CYP3A4 3133/4885ADRA2A 3178/4885 |
| US-20140323740-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 250/4885ADRA2A 906/4885 |
| US-20110136796-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 250/4885ADRA2A 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.